Pharmacist Participation in Health Policy Development Source: Council on Public Policy
To advocate that pharmacists participate with policymakers and stakeholders in the development of health-related policies at the national, state, and community levels; further,
To develop tools and resources to assist pharmacists in fully participating in health policy development at all levels.
Pharmacist Recognition as a Healthcare Provider Source: Council on Public Policy
To advocate for changes in federal (e.g., Social Security Act), state, and third-party payment programs to define pharmacists as healthcare providers; further, To affirm that pharmacists, as medication-use experts, provide safe, accessible, high-quality care that is cost effective, resulting in improved patient outcomes; further, To recognize that pharmacists, as healthcare providers, improve access to patient care and bridge existing gaps in healthcare; further, To collaborate with key stakeholders to describe the covered direct patientcare services provided by pharmacists; further,
To advocate for sustainable compensation and standardized billing processes used by payers for pharmacist services by all available payment programs.
This policy supersedes ASHP policy 1307.
Pharmaceutical Product and Supply Chain Integrity Source: Council on Public Policy
To encourage the Food and Drug Administration (FDA) and relevant state authorities to take the steps necessary to ensure that (1) all drug products entering the supply chain are thoroughly inspected and tested to establish that they have not been adulterated or misbranded and (2) patients will not receive improperly labeled and packaged, deteriorated, outdated, counterfeit, adulterated, or unapproved drug products; further, To encourage FDA and relevant state authorities to develop and implement regulations to (1) restrict or prohibit licensed drug distributors (drug wholesalers, repackagers, and manufacturers) from purchasing legend drugs from unlicensed entities and (2) ensure accurate documentation at any point in the distribution chain of the original source of drug products and chain of custody from the manufacturer to the pharmacy; further, To advocate for the establishment of meaningful penalties for companies that violate current good manufacturing practices (cGMPs) intended to ensure the quality, identity, strength, and purity of their marketed drug product(s) and raw materials; further,
To advocate for improved transparency so that drug product labeling include a readily available means to retrieve the name and location of the facility that manufac-tured the specific lot of the product; further, To advocate that this readily retrievable manufacturing information be available prospectively to aid purchasers in determining the quality of a drug product and its raw materials; further,
To urge Congress and state legislatures to provide adequate funding, or authority to impose user fees, to accomplish these objectives.
This policy supersedes ASHP policy 0907.
Patient Adherence Programs as Part of Health Insurance Coverage Source: Council on Public Policy
To advocate for the pharmacist's role in patient medication adherence programs that are part of health insurance plans; further, To advocate those programs that (1) maintain the direct patient pharmacist relationship; (2) are based on the pharmacist's knowledge of the patient's medical history, indication for the prescribed medication, and expected therapeutic outcome; (3) use a communication method desired by the patient; (4) are consistent with federal and state regulations for patient confidentiality; and (5) permit dispensing of partial fills or overfills of prescription medications in order to synchronize medication refills and aid in medication adherence.
This policy supersedes ASHP policy 0116. To advocate that the drug therapy be recommended by a physician and reviewed and monitored by a pharmacist to assure safe patient care; further, To advocate for the patient's right to be informed of the potential benefits and risks via an informed consent process, and the responsibility of an institutional review board to review and approve the informed consent and the drug therapy protocol.
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Approval of Biosimilar Medications Source: Council on Public Policy
To encourage the development of safe and effective biosimilar medications in order to make such medications more affordable and accessible; further,
To encourage research on the safety, effectiveness, and interchange-ability of biosimilar medications; further,
To support legislation and regulation to allow Food and Drug Administration (FDA) approval of biosimilar medications; further,
To support legislation and regulation to allow FDA approval of biosimilar medications that are also determined by the FDA to be interchangeable and therefore may be substituted for the reference product without the intervention of the prescriber; further,
To oppose the implementation of any state laws regarding biosimilar interchangeability prior to finalization of FDA guidance; further,
To oppose any state legislation that would require a pharmacist to notify a prescriber when a biosimilar deemed to be interchangeable by the FDA is dispensed; further, To require postmarketing surveillance for all biosimilar medications to ensure their continued safety, effectiveness, purity, quality, identity, and strength; further, To advocate for adequate reimbursement for biosimilar medications that are deemed interchangeable; further, To promote and develop ASHPdirected education of pharmacists about biosimilar medications and their appropriate use within hospitals and health systems; further, To advocate and encourage pharmacist evaluation and the application of the formulary system before biosimilar medications are used in hospitals and health systems.
This policy supersedes ASHP policy 1409.
Naloxone Availability Source: Council on Therapeutics
To recognize the potential public health benefits of naloxone for opioid reversal; further, To support efforts to safely expand access to naloxone; further, To advocate that individuals other than licensed healthcare professionals be permitted access to naloxone after receiving education; further, To foster education on the role of naloxone in opioid reversal and its proper administration, safe use, and appropriate follow-up care; further,
To support state efforts to authorize pharmacists' prescribing authority for naloxone for opioid reversal.
Complementary and Alternative Medicine in Patient Care
Source: Council on Therapeutics
To promote awareness of the impacts of complementary and alternative (CAM) products on patient care, particularly drug interactions, medication safety concerns, and the risk of contamination and variability in active ingredient content; further, To advocate for the documentation of CAM products in the health record to improve patient safety; further,
To advocate for the inclusion of information about CAM products and their characteristics in medicationrelated databases; further, To provide education on the impacts of CAM products on patient care in healthcare organizations; further,
To foster the development of up-to-date and readily available resources about CAM products.
Development of Abuse-Resistant Narcotics Source: Council on Therapeutics
To advocate that the Food and Drug Administration investigate the efficacy of abuse-resistant formulations in preventing prescription drug abuse.
Quality Patient Medication Information Source: Council on Therapeutics
To support efforts by the Food and Drug Administration (FDA) and other stakeholders to improve the quality, consistency, and simplicity of written patient medication information (PMI); further, To encourage the FDA to work in collaboration with patient advocates and other stakeholders to create evidence-based models and standards, including establishment of a universal literacy level, for PMI; further,
To advocate that research be conducted to validate these models in actual-use studies in pertinent patient populations; further, To advocate that FDA explore alternative models of PMI content development and maintenance that will ensure the highest level of accuracy, consistency, and currency; further, To advocate that the FDA engage a single third-party author to provide editorial control of a highly structured, publicly accessible central repository of PMI in a format that is suitable for ready export; further, To advocate for laws and regulations that would require all dispensers of medications to comply with FDA-established standards for unalterable content, format, and distribution of PMI.
This policy supersedes ASHP policy 1012.
Safety and Effectiveness of Ethanol Treatment for Alcohol Withdrawal Syndrome Source: Council on Therapeutics
To oppose the use of oral or intravenous ethanol for the prevention or treatment of alcohol withdrawal syndrome (AWS) because of its poor effectiveness and safety profile; further, To support hospital and healthsystem efforts that prohibit the use of oral or intravenous ethanol therapies to treat AWS; further,
To educate clinicians about the availability of alternative therapies for AWS.
This policy supersedes ASHP policy 1010.
Research on Drug Use in Obese Patients
Source: Council on Therapeutics
To encourage drug product manufacturers to conduct pharmacokinetic and pharmacodynamic research in obese patients to facilitate safe and effective dosing of medications in this patient population, especially for medications most likely to be affected by obesity; further, To encourage manufacturers to include in the Food and Drug Administration (FDA)-approved labeling detailed information on characteristics of individuals enrolled in drug dosing studies; further, To advocate that the FDA develop guidance for the design and reporting of studies that support dosing recommendations in obese patients; further,
To advocate for increased enrollment and outcomes reporting of obese patients in clinical trials of medications; further, To encourage independent research on the clinical significance of obesity on drug use, as well as the reporting and dissemination of this information via published literature, patient registries, and other mechanisms.
This policy supersedes ASHP policy 1013.
Chemotherapy Parity Source: Council on Therapeutics
To advocate that all insurance payers design plans so that patient cost sharing for chemotherapy be equivalent regardless of route of administration; further, To continue to foster the development of best practices, including adherence monitoring strategies, and education on the safe use and management of chemotherapy agents regardless of route of administration.
Documentation of Penicillin Allergy as a Component of Antimicrobial Stewardship Source: Council on Therapeutics
To advocate involvement of pharmacists in the clarification of penicillin allergy, intolerance, and adverse drug events; further,
To advocate for documentation of penicillin allergy, intolerance, reactions, and severity in the medical record to facilitate optimal antimicrobial selection; further, To recommend the use of penicillin skin testing in appropriate candidates when clinically indicated to optimize antimicrobial selection.
Developing Leadership Competencies Source: Council on Education and Workforce Development
To work with healthcare organization leadership to foster opportunities for pharmacy practitioners to move into leadership roles; further, To encourage leaders to seek out and mentor pharmacy practitioners in developing administrative, managerial, and leadership skills; further, To encourage pharmacy practitioners to obtain the skills necessary to pursue administrative, managerial, and leadership roles; further, To encourage colleges of pharmacy and ASHP state affiliates to collaborate in fostering student leadership skills through develop- To advocate for the inclusion of hospital and health-system outpatient and ambulatory care services in health insurance coverage determinations for their patients.
This policy supersedes ASHP policy 1017.
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Identification of Prescription Drug Coverage and Eligibility for Patient Assistance Programs Source: Council on Pharmacy Management
To advocate that pharmacists or pharmacy technicians ensure that the use of patient assistance programs is optimized and documented to promote continuity of care and patient access to needed medications; further, To advocate that patient assistance programs should incorporate the pharmacist-patient relationship, including evaluation by a pharmacist as part of comprehensive medication management; further,
To support the principle that medications provided through manufacturer patient assistance programs should be stored, packaged, labeled, dispensed, and recorded using systems that ensure the same level of safety as prescription-based programs that incorporate a pharmacist-patient relationship.
This policy supersedes ASHP policy 0603.
Disposition of Illicit Substances Source: Council on Pharmacy Management
To advocate that healthcare organizations be required to develop procedures for the disposition of illicit substances brought into a facility that ensure compliance with applicable laws and accreditation standards; further, To advocate that healthcare organizations be required to include pharmacy leaders in formulating such procedures.
Pharmacist's Role in Population Health Management Source: Council on Pharmacy Management
To recognize the importance of medication management in patientcare outcomes and the vital role of pharmacists in population health management; further, To encourage healthcare organizations to engage pharmacists and pharmacy leaders in identifying appropriate patient cohorts, anticipating their healthcare needs, and implementing the models of care that optimize outcomes for patients and the healthcare organization; further, To encourage the development of complexity index tools and resources to support the identification of highrisk, high-cost, and other patient cohorts to facilitate patient-care provider panel determinations and workload balancing; further, To promote collaboration among members of the interprofessional healthcare team to develop meaningful measures of individual patient and population care outcomes; further, To advocate for education to prepare pharmacists for their role in population health management.
Support for Second Victims Source: Council on Pharmacy Practice
To acknowledge that the patient is the primary victim in any medical error, unanticipated adverse patient event, or patient-related injury; further, To acknowledge that involvement by healthcare personnel in such events may cause them to become second victims; further, To recognize that a just culture and a healthy culture of safety embrace a support system for second victims; further, To encourage healthcare organizations to establish programs to support second victims; further, To educate healthcare professionals (including those in training), health organization administrators, and regulatory agencies about the secondvictim effect and available resources.
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Standardization of Doses Source: Council on Pharmacy Practice
To recognize that standardization of medication doses reduces medication errors and improves information technology interoperability, operational efficiency, and transitions of care; further,
To encourage development of universal standardized doses for specific patient populations; further, To encourage healthcare organizations to adopt standardized doses and to promote publication and education about best practices.
Prescription Drug Abuse Source: Council on Pharmacy Practice
To affirm that pharmacists have leadership roles in recognition, prevention, and treatment of prescription drug abuse; further, To promote education on prescription drug abuse, misuse, and diversion-prevention strategies. 
